Over the past two decades, small molecules have been developed to elicit mutp53 degradation through either the proteasomal or autophagic pathways, such as statins [11], NSC59984 [12], Zn(II)-curc [13] and MCB-613 [14], which exhibited effective cancer therapeutic effects, indicating that the degradation of mutp53 was a feasible strategy for p53-mutated cancer treatment. Here, TP53 is linked to cancer.